The abstract is read at the publisher; the summary is JClub's.
In a Michigan cohort of 21 people receiving a median of seven COVID-19 vaccine doses, antibody levels stayed broadly cross-reactive up to 300 days, but IgG waned formulation-specifically.
- Why it matters: It remains unclear how repeated vaccination shapes antibody breadth and durability across antigenically distinct SARS-CoV-2 variants during the Omicron era, especially with complex immune histories.
- What they did: Using multiplex serum IgG, IgM, and ACE2 percent inhibition assays, the study modeled baseline-adjusted immunogenicity, cross-reactivity, and formulation-specific waning with regression analyses.
- The result: For every two-fold higher pre-vaccination IgG, post-vaccination fold-rise was 34%, 43%, and 55% lower after monovalent, bivalent, and 2023–24 vaccination, while IgG waned after monovalent (beta = -1.03) and bivalent (beta = -1.00) and ACE2 inhibition declined after monovalent.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.